Hisamitsu Pharmaceutical Co (4530) AI Stock Analysis

• Market Cap: ¥295.50B
• Dividend Yield: 2.12%
• Average Volume (3M): 129.31K
• Price to Earnings (P/E): 13.7
• Beta (1Y): 0.23
• Revenue Growth: 10.09%
• EPS Growth: 63.28%
• Country: JP
• Employees: 2,759
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 295.76
• Shares Outstanding: 75,164,894
• 10 Day Avg. Volume: 162,480
• 30 Day Avg. Volume: 129,313
• PEG Ratio: 1.06
• Price to Book (P/B): 1.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 62.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 73 Outperform
• Price Target: ¥4,663.00 ▲(15.14%Upside)

Hisamitsu Pharmaceutical Co's financial performance is the most significant factor in its stock score, reflecting robust growth and strong financial health. Technical indicators suggest a neutral trend, while valuation metrics indicate the stock is reasonably priced with a fair dividend yield. The absence of new earnings call insights or corporate events limits additional influence on the score.

Hisamitsu Pharmaceutical Co Business Overview & Revenue Model

Company Description

Hisamitsu Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company that specializes in the development, production, and marketing of pharmaceutical products and medical devices. The company is renowned for its transdermal patch technology and is a leader in the pain relief and anti-inflammatory sectors. Its flagship products include the Salonpas line of pain relief patches, which are widely distributed both domestically and internationally.

How the Company Makes Money

Hisamitsu Pharmaceutical Co. generates revenue primarily through the sale of its transdermal drug delivery systems, with a significant portion coming from its popular Salonpas line of pain relief patches. The company markets its products globally, leveraging its strong brand recognition and established distribution networks. In addition to over-the-counter products, Hisamitsu also develops prescription medications, contributing to its revenue streams. Strategic partnerships and collaborations with other pharmaceutical companies and research institutions further enhance its product offerings and market reach, supporting its financial performance.

Hisamitsu Pharmaceutical Co Financial Statement Overview

Summary

Hisamitsu Pharmaceutical Co demonstrates solid financial health with strong revenue growth, robust profit margins, and a stable cash flow position. The company's low leverage and efficient cash conversion further indicate prudent financial management.

Income Statement

Hisamitsu Pharmaceutical Co demonstrates solid revenue growth over the past few years, with a noticeable increase from ¥114.51 billion in 2021 to ¥156.01 billion in 2025. The company maintains strong gross and net profit margins, with the latest figures for 2025 being 58.45% and 13.94%, respectively. EBIT and EBITDA margins also show substantial strength at 12.11% and 22.47% for 2025. These figures indicate a robust profitability profile, although the net profit margin could be improved slightly.

Balance Sheet

The balance sheet shows a strong equity base with stockholders' equity growing from ¥252.30 billion in 2021 to ¥276.83 billion in 2025. The debt-to-equity ratio remains low, indicating conservative leverage practices, which is favorable for financial stability. The equity ratio stands at an impressive 80.70% for 2025, showcasing the company's strong reliance on equity financing. However, the growth in total liabilities warrants close monitoring to ensure it does not outpace asset growth.

Cash Flow

Hisamitsu Pharmaceutical Co demonstrates a healthy cash flow position, with consistent operating cash flow generation, reaching ¥18.77 billion in 2025. The free cash flow remains positive, although there was a slight decrease from the peak in 2020. The company maintains a strong operating cash flow to net income ratio, indicating efficient cash conversion. The positive free cash flow trend supports the company's ability to fund operations and sustain future growth.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	150.13B	156.01B	141.71B	128.33B	120.19B	114.51B
Gross Profit	86.76B	91.20B	78.97B	72.70B	70.07B	69.17B
EBITDA	22.94B	35.05B	24.37B	16.55B	13.66B	14.75B
Net Income	15.52B	21.76B	13.97B	11.74B	9.66B	9.25B
Balance Sheet
Total Assets	334.81B	343.07B	328.78B	313.92B	302.86B	299.86B
Cash, Cash Equivalents and Short-Term Investments	116.64B	129.12B	125.32B	136.87B	142.43B	136.00B
Total Debt	2.93B	3.86B	2.10B	2.29B	2.46B	1.60B
Total Liabilities	72.51B	63.66B	61.70B	55.51B	47.98B	46.06B
Stockholders Equity	259.89B	276.83B	264.88B	256.36B	253.16B	252.29B
Cash Flow
Free Cash Flow	-892.50M	5.14B	5.15B	4.82B	15.01B	1.90B
Operating Cash Flow	4.13B	18.77B	18.19B	12.73B	19.20B	5.29B
Investing Cash Flow	2.12B	17.56B	-2.51B	-23.87B	-13.06B	7.82B
Financing Cash Flow	-6.17B	-15.85B	-16.69B	-14.69B	-15.19B	-7.19B

Hisamitsu Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4050.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4530, the sentiment is Negative. The current price of 4050 is below the 20-day moving average (MA) of 4147.25, below the 50-day MA of 4232.88, and below the 200-day MA of 4184.97, indicating a bearish trend. The MACD of -33.14 indicates Positive momentum. The RSI at 38.64 is Neutral, neither overbought nor oversold. The STOCH value of 17.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4530.

Hisamitsu Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4516	75 Outperform	¥210.01B	6.45		3.98%	8.08%	25.92%
4530	73 Outperform	¥295.50B	13.70	7.90%	2.12%	10.09%	63.28%
4887	69 Neutral	¥181.27B	18.88		2.96%	-3.69%	-18.73%
4540	69 Neutral	$263.42B	8.06	11.16%	3.95%	20.05%	94.28%
4551	65 Neutral	¥177.54B	31.98	4.56%	1.90%	9.56%	5.09%
Sector *	65 Neutral	¥345.58B	10.59	-2.88%	2.67%	11.80%	-6.84%
4506	62 Neutral	$390.54B	16.52	13.50%	―	26.79%	―

Hisamitsu Pharmaceutical Co Corporate Events

Hisamitsu Pharmaceutical Cancels 10 Million Treasury Shares to Enhance Capital Efficiency

Hisamitsu Pharmaceutical Co., Inc. has announced the cancellation of 10 million treasury shares, representing 13.70% of the total shares issued before cancellation. This move aims to improve capital efficiency, return profits to shareholders, and allow for a more flexible capital policy in response to changing business conditions.

Hisamitsu Pharmaceutical Announces New Executive Appointments

Hisamitsu Pharmaceutical Co., Inc. announced the appointment of 10 directors, including two new appointments, at its 123rd annual general meeting. This strategic move is expected to strengthen the company’s leadership and enhance its operational capabilities, potentially impacting its market position and stakeholder relations positively.

Hisamitsu Pharmaceutical Announces Board of Directors Candidates

Hisamitsu Pharmaceutical Co., Inc. announced a slate of candidates for its board of directors, to be voted on at the upcoming annual general meeting in May 2025. The announcement includes the reappointment of several current directors and the introduction of new candidates, reflecting the company’s strategic direction and governance priorities.

Hisamitsu Pharmaceutical Reports Strong Fiscal Year 2025 Results and Announces Commemorative Dividends

Hisamitsu Pharmaceutical Co. reported a significant increase in its financial performance for the fiscal year ended February 28, 2025, with net sales rising by 10.1% and profit attributable to owners of the parent increasing by 55.8%. The company also announced a commemorative dividend in celebration of the anniversaries of its flagship products, indicating a strong market position and shareholder value appreciation.